Table 3.
Cox regression analysis of ER:PR-B interactions and PR-B expression influencing relapse-free survival stratified by adjuvant endocrine agent class taken
| Endocrine agent | ER:PR-B interaction | Relapse (%) | HR | 95% CI | p Value |
|---|---|---|---|---|---|
| Tamoxifen | Low | 9 (24.3) | 1.043 | 0.348–3.135 | 0.939 |
| High | 5 (19.2) | ||||
| Aromatase inhibitor | Low | 20 (30.8) | 4.831 | 1.942–12.048 | 0.001 |
| High | 6 (7.1) | ||||
| Test for interaction | 0.031 | ||||
| PR-Bexpression | Relapse (%) | HR | 95% CI | p Value | |
| Tamoxifen | Low | 13 (36.1) | 8.929 | 1.164 – 66.667 | 0.035 |
| High | 1 (3.7) | ||||
| Aromatase inhibitor | Low | 22 (23.9) | 2.874 | 0.984 – 8.403 | 0.053 |
| High | 4 (7.0) | ||||
| Test for interaction | 0.355 |
Percentages refer to the number of patients with high or low ER:PR-B interactions or PR-B expression that had relapsed on endocrine treatment. Bold indicates significant p values